Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 94.94%
March 31, 2026 96.74%
December 31, 2025 97.28%
September 30, 2025 97.13%
June 30, 2025 96.94%
March 31, 2025 96.18%
December 31, 2024 98.35%
September 30, 2024 97.68%
June 30, 2024 49.43%
March 31, 2024 9.54%
December 31, 2023 -947.8%
September 30, 2023 0.00%
June 30, 2023 -848.3%
March 31, 2023 -1.10K%
December 31, 2022 -122.3%
September 30, 2022 0.00%
June 30, 2022 -195.9%
March 31, 2022 -60.98%
December 31, 2021 78.27%
September 30, 2021 0.00%
June 30, 2021 0.00%
March 31, 2021 0.00%
December 31, 2020 0.00%
September 30, 2020 0.00%
June 30, 2020 0.00%
Date Value
March 31, 2020 0.00%
December 31, 2019 0.00%
September 30, 2019 0.00%
June 30, 2019 0.00%
March 31, 2019 73.68%
December 31, 2018 0.00%
September 30, 2018 0.00%
June 30, 2018 0.00%
March 31, 2018 0.00%
December 31, 2017 0.00%
September 30, 2017 0.00%
June 30, 2017 0.00%
March 31, 2017 0.00%
December 31, 2016 0.00%
September 30, 2016 0.00%
June 30, 2016 0.00%
March 31, 2016 0.00%
December 31, 2015 0.00%
September 30, 2015 0.00%
June 30, 2015 0.00%
March 31, 2015 0.00%
December 31, 2014 0.00%
September 30, 2014 0.00%
June 30, 2014 0.00%
March 31, 2014 0.00%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Precigen, Inc. 94.32%
Editas Medicine, Inc. 96.50%
Agenus, Inc. 98.50%
Amgen, Inc. 72.08%
BioCryst Pharmaceuticals, Inc. 98.01%

Gross Profit Margin (Quarterly) Related Metrics